

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



康宁杰瑞

ALPHAMAB ONCOLOGY

ALPHAMAB ONCOLOGY

康寧傑瑞生物製藥

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9966)

VOLUNTARY ANNOUNCEMENT INCREASE IN SHAREHOLDING BY EXECUTIVE DIRECTOR AND MANAGEMENT

This announcement is made by Alphamab Oncology (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company has been informed by Dr. XU Ting (“**Dr. Xu**”), a controlling shareholder, the chief executive officer of the Company and an executive Director, that he purchased an aggregate of 554,000 ordinary shares of the Company (“**Shares**”) on open market on June 4, 2026 with his personal funds. In addition, certain members of the management of the Company purchased an aggregate of 122,000 Shares on the open market on June 4, 2026 and during the preceding weeks. The aggregate consideration for all Shares purchased by Dr. Xu and such management members was HK\$4,985,228, representing an average purchase price of HK\$7.375 per Share (collectively, the “**Shareholding Increase**”). Immediately after the Shareholding Increase, Dr. Xu directly and indirectly hold an aggregate of 314,288,840 Shares, representing approximately 32.4% of the total issued Shares (excluding treasury Shares) of the Company.

Dr. Xu stated that the Shareholding Increase was made based on the firm confidence of the Director and management in the Company’s future prospects and long-term development. The current trading price does not reflect the intrinsic value of the Company. Specifically, the Company’s product KN026 was approved for marketing in China in May 2026 for second-line and later-line treatment of HER2+ GC/GEJ, and the significant results of the phase III clinical study of KN026 as neoadjuvant treatment for HER2+ BC were presented at the LBA Oral Presentation Session of the 2026 ASCO Annual Meeting.

Currently, multiple registrational clinical studies are progressing smoothly across a range of indications, including KN026 for first-line HER2+ BC, neoadjuvant and adjuvant treatment of HER2+ BC, and first-line HER2+ GC/GEJ; JSKN003 for second-line HER2+ BC, second-line and later HER2 low expressing BC, all comer PROC and HER2+ CRC; and JSKN016 for later-line TNBC. Multiple combination therapy studies of JSKN016 and multiple phase II clinical studies of JSKN033 are also progressing smoothly. Among the Company’s early-stage ADC products, patient enrollment for both JSKN022, JSKN027 and JSKN021 is progressing actively. More than 30 patients enrolled for JSKN022, with preliminary safety and efficacy demonstrated. For all products in pipeline, the Company is actively exploring multiple global development strategies. The Company will continue to accelerate the advancement of its clinical programs and create sustained value for patients and Shareholders. Subject to compliance with applicable laws and regulations, Dr. Xu and such management members do not rule out the possibility of further increasing their shareholdings in the Company as and when appropriate.

The Company also repurchased 156,000 Shares on the same date, demonstrating its confidence in its own business outlook and prospects. Please refer to the separate announcement of the Company dated June 5, 2026 for details.

Based on the information available to the Company and to the knowledge of the Board, following the completions of the Shareholding Increase, the Company maintains a sufficient public float of its issued Shares in compliance with the applicable laws, rules and provisions, including the Rule 8.08 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”); and the Shareholding Increase has been conducted in compliance with the Model Code for Securities Transactions by Directors of Listed Issuers as set out in Appendix C3 of the Listing Rules.

By Order of the Board
Alphamab Oncology
Dr. XU Ting
Chairman and Executive Director

Hong Kong, June 5, 2026

As at the date of this announcement, the Board comprises Dr. XU Ting as the chairman of the Board and executive Director and Ms. LIU Yang as executive Director, Mr. CHO Man as non-executive Director, and Mr. WU Dong, Ms. WONG Yan Ki Angel and Dr. GAO Xiang as independent non-executive Directors.